Galectin Therapeutics (GALT) grants CMO and CFO 2026 retention bonuses

Rhea-AI Filing Summary

Galectin Therapeutics Inc. reported that its board of directors, following a recommendation from the compensation committee, approved cash retention bonuses for two senior executives. The Chief Medical Officer, Dr. Khurram Jamil, was granted a $300,000 cash retention bonus, and the Chief Financial Officer, Jack Callicutt, was granted a $150,000 cash retention bonus.

The bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026. Each officer must repay the full retention bonus if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, consistent with their employment agreements. This structure is designed to encourage continuity in these key leadership roles through the end of 2026.

false000113341600011334162026-01-162026-01-16

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 16, 2026

GALECTIN THERAPEUTICS INC

(Exact name of registrant as specified in its charter)

Nevada	001-31791	04-3562325
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

4960 PEACHTREE INDUSTRIAL BOULEVARD, STE 240

NORCROSS, GA 30071

(Address of principal executive office) (zip code)

Registrant’s telephone number, including area code: (678) 620-3186

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
Common Stock $0.001 par value per share		GALT		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On January 16, 2026, at the recommendation of the Company’s compensation committee, the Company’s board of directors approved a $300,000 cash retention bonus for the Company’s Chief Medical Officer, Dr. Khurram Jamil, and a $150,000 cash retention bonus for the Company’s Chief Financial Officer, Jack Callicutt.   The retention bonuses will be paid in 3 equal payments on each of June 1, 2026, September 1, 2026 and December 1, 2026.  These retention bonuses are required to be paid back to the Company by the officers if they voluntarily resign without good reason or are terminated for cause, as described in their respective employment agreements, prior to December 31, 2026.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, Galectin Therapeutics Inc. has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	GALECTIN THERAPEUTICS INC.
Date: January 21, 2026	By:	/s/ Jack W. Callicutt
		Jack W. Callicutt
		Chief Financial Officer

FAQ

What executive bonuses did Galectin Therapeutics (GALT) approve in this 8-K?

Galectin Therapeutics approved a $300,000 cash retention bonus for its Chief Medical Officer, Dr. Khurram Jamil, and a $150,000 cash retention bonus for its Chief Financial Officer, Jack Callicutt.

How and when will the Galectin Therapeutics (GALT) retention bonuses be paid?

The retention bonuses will be paid in three equal installments on June 1, 2026, September 1, 2026 and December 1, 2026.

What conditions apply to the retention bonuses for GALT’s CMO and CFO?

The officers must repay the retention bonuses if they voluntarily resign without good reason or are terminated for cause before December 31, 2026, as defined in their employment agreements.

Which Galectin Therapeutics executives are covered by the new retention bonuses?

The new retention bonuses apply to Chief Medical Officer Dr. Khurram Jamil and Chief Financial Officer Jack Callicutt.

Who approved the Galectin Therapeutics (GALT) retention bonuses?

The compensation committee recommended the bonuses, and the board of directors of Galectin Therapeutics approved them.

Does the 8-K indicate any change to Galectin Therapeutics’ common stock listing?

The filing states that Galectin Therapeutics’ common stock continues to trade on The Nasdaq Stock Market under the symbol GALT.